|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/28 | |
| A61K 9/48 | |||
| A61K 31/519 | |||
| A61P 1/04 | |||
| A61P 17/06 | |||
| A61P 19/02 | |||
| A61P 37/06 |
| (11) | Patento numeris | 2968155 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14726410.5 |
| Europos patento paraiškos padavimo data | 2014-03-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-01-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-03-03 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2014/059689 |
| Data | 2014-03-12 |
| (87) | Numeris | WO 2014/147526 |
| Data | 2014-09-25 |
| (30) | Numeris | Data | Šalis |
| 201361802479 P | 2013-03-16 | US | |
| 201361864059 P | 2013-08-09 | US | |
| 201461934428 P | 2014-01-31 | US |
| (72) |
HERBIG, Scott Max, US
KRISHNASWAMI, Sriram, US
KUSHNER IV, Joseph, US
LAMBA, Manisha, US
STOCK, Thomas C., US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS |
| TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS |